Search

Your search keyword '"Straughn, J Michael"' showing total 463 results
Start Over Author "Straughn, J Michael"
463 results on '"Straughn, J Michael"'

8. A cost–utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer

Author

Cohn, David E, Barnett, Jason C, Wenzel, Lari, Monk, Bradley J, Burger, Robert A, Straughn, J Michael, Myers, Evan R, and Havrilesky, Laura J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Comparative Effectiveness Research, Ovarian Cancer, Cancer, Cost Effectiveness Research, Clinical Research, Rare Diseases, Digestive Diseases, Good Health and Well Being, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carboplatin, Clinical Trials as Topic, Cost-Benefit Analysis, Disease-Free Survival, Female, Humans, Markov Chains, Models, Economic, Neoplasm Staging, Ovarian Neoplasms, Paclitaxel, Prospective Studies, Quality of Life, Survival Analysis, United States, Cost-utility analysis, NRG Oncology, GOG Oncology Group, Quality-of-life, Ovarian cancer, Cost–utility analysis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectiveTo estimate quality-of-life (QOL)-adjusted cost-utility with addition of bevacizumab (B) to intravenous paclitaxel/carboplatin (PC) for primary treatment of advanced-stage epithelial ovarian cancer.MethodsA modified Markov state transition model of 3 regimens evaluated in GOG 218 (PC, PC+concurrent B [PCB], and PCB+maintenance B [PCB+B]) was populated by prospectively collected survival, adverse event, and QOL data from GOG 218. Progression-free survival (PFS) and overall survival (OS) were modeled using primary event data. Costs of grade 4 hypertension, grade 3-5 bowel events, and growth factor support were incorporated. QOL scores were converted to utilities and incorporated into the model. Monte Carlo probabilistic sensitivity analysis was performed to account for uncertainty in estimates.ResultsPC was the least expensive ($4044) and least effective (mean 1.1 quality-adjusted progression-free years [QA-PFY]) regimen. PCB ($43,703 and 1.13 QA-PFY) was dominated by a combination of PC and PCB+B. PCB+B ($122,700 and 1.25 QA-PFY) was the most expensive regimen with an incremental cost-effectiveness ratio of $792,380/QA-PFY compared to PC. In a model not incorporating QOL, the incremental cost-effectiveness ratio (ICER) of PCB+B was $632,571/PFY compared to PC.ConclusionsIn this cost-utility model, incorporation of QOL into an analysis of GOG 218 led to less favorable ICER (by >$150,000/QA-PFY) in regimens containing B compared with those that do not include B. Continued investigation of populations with ovarian cancer in whom the efficacy of treatment with bevacizumab is expected to be increased (or in whom QOL is expected to increase with use) is critical.

Published
2015

16. Supplementary Figure 5 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Author

Arend, Rebecca C., primary, Londoño, Angelina I., primary, Montgomery, Allison M., primary, Smith, Haller J., primary, Dobbin, Zachary C., primary, Katre, Ashwini A., primary, Martinez, Alba, primary, Yang, Eddy S., primary, Alvarez, Ronald D., primary, Huh, Warner K., primary, Bevis, Kerri S., primary, Straughn, J. Michael, primary, Estes, Jacob M., primary, Novak, Lea, primary, Crossman, David K., primary, Cooper, Sara J., primary, Landen, Charles N., primary, and Leath, Charles A., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Tables 1 - 7 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Author

Arend, Rebecca C., primary, Londoño, Angelina I., primary, Montgomery, Allison M., primary, Smith, Haller J., primary, Dobbin, Zachary C., primary, Katre, Ashwini A., primary, Martinez, Alba, primary, Yang, Eddy S., primary, Alvarez, Ronald D., primary, Huh, Warner K., primary, Bevis, Kerri S., primary, Straughn, J. Michael, primary, Estes, Jacob M., primary, Novak, Lea, primary, Crossman, David K., primary, Cooper, Sara J., primary, Landen, Charles N., primary, and Leath, Charles A., primary

Published
2023
Full Text
View/download PDF

18. Data from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Author

Arend, Rebecca C., primary, Londoño, Angelina I., primary, Montgomery, Allison M., primary, Smith, Haller J., primary, Dobbin, Zachary C., primary, Katre, Ashwini A., primary, Martinez, Alba, primary, Yang, Eddy S., primary, Alvarez, Ronald D., primary, Huh, Warner K., primary, Bevis, Kerri S., primary, Straughn, J. Michael, primary, Estes, Jacob M., primary, Novak, Lea, primary, Crossman, David K., primary, Cooper, Sara J., primary, Landen, Charles N., primary, and Leath, Charles A., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 2 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Author

Arend, Rebecca C., primary, Londoño, Angelina I., primary, Montgomery, Allison M., primary, Smith, Haller J., primary, Dobbin, Zachary C., primary, Katre, Ashwini A., primary, Martinez, Alba, primary, Yang, Eddy S., primary, Alvarez, Ronald D., primary, Huh, Warner K., primary, Bevis, Kerri S., primary, Straughn, J. Michael, primary, Estes, Jacob M., primary, Novak, Lea, primary, Crossman, David K., primary, Cooper, Sara J., primary, Landen, Charles N., primary, and Leath, Charles A., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 1 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Author

Arend, Rebecca C., primary, Londoño, Angelina I., primary, Montgomery, Allison M., primary, Smith, Haller J., primary, Dobbin, Zachary C., primary, Katre, Ashwini A., primary, Martinez, Alba, primary, Yang, Eddy S., primary, Alvarez, Ronald D., primary, Huh, Warner K., primary, Bevis, Kerri S., primary, Straughn, J. Michael, primary, Estes, Jacob M., primary, Novak, Lea, primary, Crossman, David K., primary, Cooper, Sara J., primary, Landen, Charles N., primary, and Leath, Charles A., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table, Figure Legends from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Author

Arend, Rebecca C., primary, Londoño, Angelina I., primary, Montgomery, Allison M., primary, Smith, Haller J., primary, Dobbin, Zachary C., primary, Katre, Ashwini A., primary, Martinez, Alba, primary, Yang, Eddy S., primary, Alvarez, Ronald D., primary, Huh, Warner K., primary, Bevis, Kerri S., primary, Straughn, J. Michael, primary, Estes, Jacob M., primary, Novak, Lea, primary, Crossman, David K., primary, Cooper, Sara J., primary, Landen, Charles N., primary, and Leath, Charles A., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 3 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Author

Arend, Rebecca C., primary, Londoño, Angelina I., primary, Montgomery, Allison M., primary, Smith, Haller J., primary, Dobbin, Zachary C., primary, Katre, Ashwini A., primary, Martinez, Alba, primary, Yang, Eddy S., primary, Alvarez, Ronald D., primary, Huh, Warner K., primary, Bevis, Kerri S., primary, Straughn, J. Michael, primary, Estes, Jacob M., primary, Novak, Lea, primary, Crossman, David K., primary, Cooper, Sara J., primary, Landen, Charles N., primary, and Leath, Charles A., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 4 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Author

Arend, Rebecca C., primary, Londoño, Angelina I., primary, Montgomery, Allison M., primary, Smith, Haller J., primary, Dobbin, Zachary C., primary, Katre, Ashwini A., primary, Martinez, Alba, primary, Yang, Eddy S., primary, Alvarez, Ronald D., primary, Huh, Warner K., primary, Bevis, Kerri S., primary, Straughn, J. Michael, primary, Estes, Jacob M., primary, Novak, Lea, primary, Crossman, David K., primary, Cooper, Sara J., primary, Landen, Charles N., primary, and Leath, Charles A., primary

Published
2023
Full Text
View/download PDF

36. Endometrial Cancer

Author

Straughn, J. Michael, Jr., Partridge, Edward E., Bland, Kirby I., editor, Büchler, Markus W., editor, Csendes, Attila, editor, Sarr, Michael G., editor, Garden, O. James, editor, and Wong, John, editor

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results